Trial Profile
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of SPN-812 ER for the Treatment of Pediatric Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Apr 2023
Price :
$35
*
At a glance
- Drugs Viloxazine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions; Registrational
- Sponsors Supernus Pharmaceuticals
- 13 Apr 2023 Planned End Date changed from 1 Jun 2024 to 1 Jun 2025.
- 13 Apr 2023 Planned primary completion date changed from 1 Jun 2024 to 1 Jun 2025.
- 01 Mar 2021 Planned End Date changed from 1 Jun 2021 to 1 Jun 2024.